Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions

A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908)

(2016) Clive S. Zent et al.   AMERICAN JOURNAL OF HEMATOLOGY

Real-time analysis of the detailed sequence of cellular events in mAb-mediated complement-dependent cytotoxicity of B-cell lines and of chronic lymphocytic leukemia B-cells

(2016) Margaret A. Lindorfer et al.   MOLECULAR IMMUNOLOGY

A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface

(2016) Rob N. de Jong et al.   PLOS BIOLOGY

Complement in hemolytic anemia

(2015) R. A. Brodsky   BLOOD

Complement in therapy and disease

(2015) Joost P.M. Melis et al.   MOLECULAR IMMUNOLOGY

Complement, a target for therapy in inflammatory and degenerative diseases

(2015) B. Paul Morgan et al.   NATURE REVIEWS DRUG DISCOVERY

Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells

(2014) Clive S. Zent et al.   AMERICAN JOURNAL OF HEMATOLOGY

Antibody Fc engineering improves frequency and promotes kinetic boosting of serial killing mediated by NK cells

(2014) G. Romain et al.   BLOOD

Induced Resistance to Ofatumumab-Mediated Cell Clearance Mechanisms, Including Complement-Dependent Cytotoxicity, in Chronic Lymphocytic Leukemia

(2014) N. A. Baig et al.   JOURNAL OF IMMUNOLOGY

Complement Is Activated by IgG Hexamers Assembled at the Cell Surface

(2014) C. A. Diebolder et al.   SCIENCE

The role of complement in mAb-based therapies of cancer

(2013) Ronald P. Taylor et al.   METHODS

A simple, robust and highly efficient transient expression system for producing antibodies

(2013) Tom Vink et al.   METHODS

Boosting ADCC and CDC activity by Fc engineering and evaluation of antibody effector functions

(2013) Christian Kellner et al.   METHODS

Activation of complement by monoclonal antibodies that target cell-associated β2-microglobulin: Implications for cancer immunotherapy

(2013) Michael J. Pokrass et al.   MOLECULAR IMMUNOLOGY

Mechanism of action of therapeutic monoclonal antibodies: Promises and pitfalls of in vitro and in vivo assays

(2012) Josée Golay et al.   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

Caveolin-1 and Dynamin-2 Are Essential for Removal of the Complement C5b-9 Complex via Endocytosis

(2012) Oren Moskovich et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Ofatumumab Is More Efficient than Rituximab in Lysing B Chronic Lymphocytic Leukemia Cells in Whole Blood and in Combination with Chemotherapy

(2012) L. Bologna et al.   JOURNAL OF IMMUNOLOGY

Exhaustion of Cytotoxic Effector Systems May Limit Monoclonal Antibody-Based Immunotherapy in Cancer Patients

(2012) F. J. Beurskens et al.   JOURNAL OF IMMUNOLOGY

Complement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement

(2012) Nisar A. Baig et al.   LEUKEMIA & LYMPHOMA

Monoclonal antibody (mAb)-based cancer therapy

(2012) Margaret A. Lindorfer et al.   OncoImmunology

Penetration of antibody-opsonized cells by the membrane attack complex of complement promotes Ca2+ influx and induces streamers

(2011) Paul V. Beum et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

(2010) E. Mossner et al.   BLOOD

HuMab-7D8, a monoclonal antibody directed against the membrane-proximal small loop epitope of CD20 can effectively eliminate CD20low expressing tumor cells that resist rituximab-mediated lysis

(2010) T. van Meerten et al.   HAEMATOLOGICA

Binding of Submaximal C1q Promotes Complement-Dependent Cytotoxicity (CDC) of B Cells Opsonized with Anti-CD20 mAbs Ofatumumab (OFA) or Rituximab (RTX): Considerably Higher Levels of CDC Are Induced by OFA than by RTX

(2009) A. W. Pawluczkowycz et al.   JOURNAL OF IMMUNOLOGY

Cancer resistance to complement-dependent cytotoxicity (CDC): Problem-oriented research and development

(2009) Dana Gancz et al.   MOLECULAR IMMUNOLOGY

The impact of Fc engineering on an anti-CD19 antibody: increased Fc  receptor affinity enhances B-cell clearing in nonhuman primates

(2008) J. Zalevsky et al.   BLOOD

Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early–intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab

(2008) Clive S. Zent et al.   LEUKEMIA RESEARCH